These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11497350)

  • 21. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
    Morishita R; Tomita N; Kaneda Y; Ogihara T
    Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line.
    Fei R; Shaoyang L
    Gynecol Oncol; 2002 Apr; 85(1):40-4. PubMed ID: 11925118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential therapeutic applications of decoy oligonucleotides.
    Tomita N; Morishita R; Tomita T; Ogihara T
    Curr Opin Mol Ther; 2002 Apr; 4(2):166-70. PubMed ID: 12044038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PEG-appended beta-(1-->3)-D-glucan schizophyllan to deliver antisense-oligonucleotides with avoiding lysosomal degradation.
    Karinaga R; Koumoto K; Mizu M; Anada T; Shinkai S; Sakurai K
    Biomaterials; 2005 Aug; 26(23):4866-73. PubMed ID: 15763266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prospects for antisense therapy].
    Maekawa T
    Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C IRES: translating translation into a therapeutic target.
    Jubin R
    Curr Opin Mol Ther; 2001 Jun; 3(3):278-87. PubMed ID: 11497352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor.
    Ou X; Tan T; He L; Li Y; Li J; Kuang A
    Cancer Gene Ther; 2005 Mar; 12(3):313-20. PubMed ID: 15578065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II.
    Fluiter K; ten Asbroek AL; van Groenigen M; Nooij M; Aalders MC; Baas F
    Cancer Res; 2002 Apr; 62(7):2024-8. PubMed ID: 11929820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense effects in the cell nucleus: modification of splicing.
    Kole R; Sazani P
    Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antisense constructs, therapeutics of the future?].
    Van Aerschot A
    Verh K Acad Geneeskd Belg; 2000; 62(6):565-601. PubMed ID: 11196580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant adeno-associated virus-mediated delivery of antisense angiotensin II receptor 1 gene attenuates hypertension development.
    Li XG; Yan JT; Xu XZ; Wang JN; Cheng LM; Wang T; Zuo P; Wang DW
    Acta Pharmacol Sin; 2007 Nov; 28(11):1737-45. PubMed ID: 17959024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of telomerase with human telomerase reverse transcriptase antisense enhances tumor necrosis factor-alpha-induced apoptosis in bladder cancer cells.
    Gao XD; Chen YR
    Chin Med J (Engl); 2007 May; 120(9):755-60. PubMed ID: 17531113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
    Tolcher AW
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense studies of brain GABAA receptors.
    Karle J
    Dan Med Bull; 2002 May; 49(2):130-44. PubMed ID: 12064090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.